IntReALL-BCP-2020 (ALL)
Clinical study on the treatment of children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL).
Recruiting
Who can enter
Children with first relapse B-cell acute lymphoblastic leukemia (B-ALL)
Age: between 0 and 21 years old
Goal
The goal of this study is to improve the treatment for patients with a relapsed B-ALL and to reduce the side effects.
Background
When ALL relapses, a long treatment with chemotherapy, and for some children a stem cell transplantation, is needed again. Currently, despite this treatment, we are not able to cure all the children whose ALL relapses.
In recent years, new medicinal products have become available that may improve treatment. These medications usually cause fewer severe side effects than chemotherapy. In this research, we are investigating whether the drugs 'inotuzumab ozogamicin' and 'blinatumomab' improve treatment.
For standard-risk patients:
We are investigating whether administering inotuzumab ozogamicin in the first 4 weeks after diagnosis results in a better outcome than 4 weeks of chemotherapy.
We are investigating whether treatment outcomes are better if we replace a 4 week chemotherapy cycle with blinatumomab at three points during the treatment.
For high-risk patients:
We are investigating whether one cycle of chemotherapy followed by one cycle of blinatumomab results in the same outcome as two cycles of chemotherapy followed by one cycle of blinatumomab.
For patients with a relapse outside the bone marrow:
We are investigating whether treatment outcomes are better if we replace one 4-week chemotherapy cycle with blinatumomab.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
October 15, 2026
Study details
- Study details
Official title
“International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020”
Cancer type
First relapse ALLPhase
3Maximum number of participants
750, of whom 25 are expected to participate in the NetherlandsStart date
October 15, 2026Status
OpenLocal principal investigator
Dr. J. StutterheimSponsor
Charité – Medical University of BerlinApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
EU Clinical Trials: 2023-509392-17-00
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.